EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study

Shilong Deng iD, Xue Yan, Ying Peng, Lijun Zhu, Yongshi Shen, Wenmin Ying, Yuanji Xu iD, Zhichao Fu

Cancers · 01.01.2026 · 18 (1) · 155

DOI: 10.3390/cancers18010155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 01.01.2026. Verfasst von Shilong Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wu Jieping Medical Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) have poor prognosis after surgery. Neoadjuvant chemoimmunotherapy (nCIT) and neoadjuvant chemoradiotherapy (nCRT) may improve outcomes, but their long-term efficacy remains unclear.

Methods

This multicenter study analyzed LA-ESCC patients from three Chinese hospitals (2015–2024) who received nCIT or nCRT followed by surgery. Primary endpoint was 3-year overall survival (OS); secondary endpoints included objective response rate (ORR), pathologic complete response (pCR), disease-free survival (DFS), and adverse events. Propensity score matching balanced baseline characteristics.

Results

Among 225 patients (87 nCRT, 138 nCIT), matched cohorts (87 per group) showed that nCRT had higher ORR (85.06% vs. 45.98%), T/N downstaging rates (78.16% vs. 58.62%; 85.06% vs. 45.98%), and pCR (37.90% vs. 14.90%) (all p < 0.01). After median follow-up (nCIT: 44.5 months; nCRT: 35.1 months), nCIT improved 3-year OS (75.90% vs. 55.60%) and DFS (66.40% vs. 47.30%) (p < 0.05). Subgroup analysis favored nCRT in N+ or non-cT4 disease. Clinical N stage independently predicted survival. Conclusion: nCIT demonstrates superior survival benefits in LA-ESCC, while nCRT may be more effective for N+ or non-cT4 patients. Further randomized trials are warranted.

Schlagwörter

Stichwörter der Autor:innen

immunotherapylocally advanced resectable esophageal squamous cell carcinomaneoadjuvant chemoradiotherapysurvival

Autor:innen und Institutionen

  • Department of Radiotherapy, Fuzong Clinical Medical College of Fujian Medical University, Fujian Medical University, Fuzhou 350025, China.
  • Department of Radiotherapy, 900th Hospital of PLA Joint Logistic Support Force, Fuzhou 350025, China.
  • Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China.
  • Department of Radiotherapy, Fuding Hospital, Fuding 355200, China.

ORCID-Profile: Shilong Deng, Yuanji Xu

Förderung

  • Wu Jieping Medical Foundation

Zitieren

APA

Deng, S., Yan, X., Peng, Y., Zhu, L., Shen, Y., Ying, W., Xu, Y., & Fu, Z. (2026). Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study. Cancers, 18(1), 155. https://doi.org/10.3390/cancers18010155

Vancouver

Deng S, Yan X, Peng Y, Zhu L, Shen Y, Ying W, et al. Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study. Cancers. 2026;18(1):155. doi:10.3390/cancers18010155

BibTeX
@article{Deng2026,
  author = {Deng, Shilong and Yan, Xue and Peng, Ying and Zhu, Lijun and Shen, Yongshi and Ying, Wenmin and Xu, Yuanji and Fu, Zhichao},
  title = {Three-Year Outcomes of Neoadjuvant Chemoimmunotherapy vs. Neoadjuvant Chemoradiotherapy in Resectable Esophageal Cancer: A Multicenter Retrospective Study},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {1},
  pages = {155},
  doi = {10.3390/cancers18010155}
}
Kostenlos starten →